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background
 
Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity
in advanced breast cancer that overexpresses HER2. We investigated its efficacy and
safety after excision of early-stage breast cancer and completion of chemotherapy.
 
methods
 
This international, multicenter, randomized trial compared one or two years of tras-
tuzumab given every three weeks with observation in patients with HER2-positive and
either node-negative or node-positive breast cancer who had completed locoregional
therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy.
 
results
 
Data were available for 1694 women randomly assigned to two years of treatment with
trastuzumab, 1694 women assigned to one year of trastuzumab, and 1693 women as-
signed to observation. We report here the results only of treatment with trastuzumab
for one year or observation. At the first planned interim analysis (median follow-up of
one year), 347 events (recurrence of breast cancer, contralateral breast cancer, second
nonbreast malignant disease, or death) were observed: 127 events in the trastuzumab
group and 220 in the observation group. The unadjusted hazard ratio for an event in
the trastuzumab group, as compared with the observation group, was 0.54 (95 percent
confidence interval, 0.43 to 0.67; P<0.0001 by the log-rank test, crossing the interim
analysis boundary), representing an absolute benefit in terms of disease-free survival at
two years of 8.4 percentage points. Overall survival in the two groups was not signifi-
cantly different (29 deaths with trastuzumab vs. 37 with observation). Severe car-
diotoxicity developed in 0.5 percent of the women who were treated with trastuzumab.
 
conclusions
 
One year of treatment with trastuzumab after adjuvant chemotherapy significantly
improves disease-free survival among women with HER2-positive breast cancer.
(clinicaltrials.gov number, NCT 00045032.)
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ER2/
 
neu
 
 
 
(hereafter referred to as
 
HER2) belongs to a family of four trans-
membrane receptor tyrosine kinases that
mediate the growth, differentiation, and survival of
cells.
 
1,2
 
 Overexpression of the HER2 protein, ampli-
fication of the 
 
HER2
 
 gene, or both occur in approxi-
mately 15 to 25 percent of breast cancers, and are as-
sociated with aggressive behavior in the tumor.
 
3,4
 
Trastuzumab (Herceptin, Roche), a humanized
monoclonal antibody against the extracellular do-
main of HER2, has been shown to benefit patients
with HER2-positive metastatic breast cancer when
administered weekly or every three weeks, alone
 
5,6
 
or in combination with chemotherapy.
 
7,8 
 
Trastuz-
umab is not associated with the adverse events that
typically occur with chemotherapy, such as alopecia,
myelosuppression, and severe nausea and vomit-
ing.
 
9
 
 With the exception of hypersensitivity, which
has been seen mainly and occasionally with the first
infusion, cardiotoxicity (principally congestive heart
failure) is the most important adverse effect of tras-
tuzumab. Cardiotoxicity has been reported in 1.4
percent of women who received the drug as a single
agent for metastatic disease.
 
5,6
 
 The adverse effect
of the interaction between trastuzumab and anthra-
cyclines on the heart
 
7
 
 and the lesser adverse effect of
the interaction between trastuzumab and taxanes
 
7,8
 
are concerns in the design and conduct of studies
of adjuvant therapy, given the established activity
and central role of anthracyclines and taxanes in
the treatment of breast cancer. For this reason, in-
vestigations of trastuzumab in the adjuvant setting
require careful cardiac monitoring and stopping
rules specified for cardiotoxicity.
Our group investigated whether the administra-
tion of trastuzumab was effective as adjuvant treat-
ment for HER2-positive breast cancer if used after
completion of the primary treatment (e.g., surgery,
radiotherapy, and chemotherapy given preopera-
tively [neoadjuvant], postoperatively [adjuvant], or
both). The administration of trastuzumab after che-
motherapy permits the application of our findings
to the wide variety of chemotherapy regimens used
throughout the world.
 
10
 
 In our trial, one group of
women received trastuzumab for one year and an-
other group received the drug for two years. We in-
cluded these two groups for three reasons: a major
peak in the rate of relapse occurs 18 to 24 months
after surgery,
 
11
 
 effective treatment of HER2-positive
breast cancer may require prolonged attenuation of
HER2 activity,
 
12
 
 and tamoxifen, which is an effective
targeted therapy for breast cancer, is most benefi-
cial when given for longer than one year.
 
13
 
 We re-
port a comparison of the results obtained with
observation or with one year of trastuzumab after
primary treatment of breast cancer.
 
study design
 
The Herceptin Adjuvant (HERA) (Breast Interna-
tional Group [BIG] 01-01) Trial is an international,
intergroup, open-label, phase 3 randomized trial in-
volving women with HER2-positive (overexpress-
ing or amplified) early-stage invasive breast cancer
who completed locoregional therapy (surgery with
or without radiotherapy) and a minimum of four
courses of chemotherapy (administered as adjuvant
treatment postoperatively among 89 percent of the
women, or as neoadjuvant treatment preoperatively
among 5 percent of the women, or as both adjuvant
and neoadjuvant chemotherapy among 6 percent of
the women) (Fig. 1). The HER2-positive status of
the tumors was centrally confirmed in all cases be-
fore randomization. The trial included three groups:
women who had observation alone; those treated
with trastuzumab, given as adjuvant treatment (at
a dose of 8 mg per kilogram of body weight intrave-
nously once, then at a dose of 6 mg per kilogram ev-
ery three weeks) for two years; and those treated
with trastuzumab at the same dose and on the same
schedule for one year. Random assignment to one of
the three groups was performed within seven weeks
from day 1 of the last chemotherapy cycle or six
weeks from the end of radiotherapy or definitive sur-
gery, whichever was last. A minimization procedure,
according to the methods of Pocock and Simon,
 
14
 
was used with stratification according to region of
the world, age, nodal status, type of chemotherapy,
and hormone-receptor status together with inten-
tion to use endocrine therapy (Table 1).
The primary end point was disease-free survival,
defined as time from randomization to the first oc-
currence of any of the following disease-free–surviv-
al events: recurrence of breast cancer at any site; the
development of ipsilateral or contralateral breast
cancer, including ductal carcinoma in situ but not
lobular carcinoma in situ; second nonbreast malig-
nant disease other than basal-cell or squamous-cell
carcinoma of the skin or carcinoma in situ of the
cervix; or death from any cause without documen-
tation of a cancer-related event. Secondary end
points included cardiac safety, overall survival, site
of first disease-free–survival event, and time to dis-
h
methods
The New England Journal of Medicine 
Downloaded from nejm.org on March 21, 2018. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
353;16
 
www.nejm.org october 
 
20, 2005
 
trastuzumab after chemotherapy for her2-positive breast cancer
 
1661
 
tant recurrence, defined as the time between ran-
domization and the date of the first distant tumor
recurrence, ignoring locoregional recurrences and
second breast or nonbreast cancers and taking into
account deaths before recurrence of distant breast
cancer as censoring events.
The study was conducted under the auspices of
the BIG and involved the collaboration of 17 BIG
groups, 9 other cooperative groups, 91 independent
centers, and the pharmaceutical sponsor, Roche, all
of which were represented in the steering commit-
tee of the HERA trial. The study was designed by
members of the steering committee. The database
resided in a system of the sponsor, and access was
restricted to data managers of the Breast European
Adjuvant Study Team data center and statisticians
of Frontier Science (Scotland). The sponsor had no
access to the database or the interim analyses. The
analyses were presented by the independent statis-
ticians to the independent data monitoring com-
mittee without disclosure to the data center, the
investigators, or the sponsor. The HERA steering
committee was responsible for the decision to pub-
lish and for the content of the manuscript. The
sponsor provided the drug and financial support.
The institutional review board at each of the 478
participating institutions in 39 countries approved
the study protocol. All patients gave written in-
formed consent.
 
eligibility criteria
 
Eligible patients had histologically confirmed, com-
pletely excised invasive breast cancer with HER2
overexpression or 
 
HER2
 
 amplification as assessed in
the participating institution and verified in the cen-
tral laboratory of the trial (Kassel, Germany). A
result on immunohistochemical analysis (IHC)
at the central laboratory (Herceptest, Dako) of 3+
(IHC 3+), in a range from 0 to 3+ with higher values
indicating increased overexpression, was required
for confirmation of the status of tumors assessed
at the participating institution as IHC 3+, and a
positive result on fluorescence in situ hybridization
(FISH) for 
 
HER2
 
 amplification (PathVision, Vysis)
at the central laboratory was required for tumors
that were assessed in the participating institution
as IHC 2+ or FISH-positive.
The hormone-receptor status of the tumor was
determined and the tumor tissue was accessible for
central review. Eligible patients had node-positive
disease (irrespective of pathological tumor size) or
node-negative disease (including only a negative
sentinel node) if on pathological examination the
tumor size was larger than 1 cm.
Adjuvant chemotherapy, neoadjuvant chemo-
therapy, or both, selected from a list of approved
regimens consisting of at least four cycles (described
in detail in Supplementary Appendix 1, available
with the full text of this article at www.nejm.org),
was completed before randomization. Adjuvant
endocrine therapy, primarily tamoxifen, was given
after chemotherapy to women with hormone-recep-
tor–positive disease unless contraindicated. During
the course of the trial, an amendment to the proto-
col allowed aromatase inhibitors to be used instead
of, or in sequence with, tamoxifen.
Patients were required to have adequate baseline
hepatic, renal, and bone marrow function. Patients
were required to use adequate non–hormone-based
contraceptive measures, if indicated. Patients were
excluded if they had distant metastases, a previous
invasive breast carcinoma, or a neoplasm not involv-
ing the breast, except for curatively treated basal-cell
or squamous-cell carcinoma of the skin or in situ
carcinoma of the cervix. Patients with clinical stage
T4 tumors, including inflammatory breast cancers
or involvement of supraclavicular nodes, were not
eligible. Suspicious internal mammary nodes were
an exclusion criterion, unless they were subjected to
radiotherapy. Prior mediastinal irradiation (except
internal mammary-node irradiation for the present
breast cancer) and cumulative doses of anthracy-
cline exceeding 360 mg per square meter of body-
surface area for doxorubicin, or 720 mg per square
meter for epirubicin or stem-cell support for che-
motherapy were also exclusion criteria.
Only patients who, after completion of all che-
motherapy and radiotherapy, had a normal left
ventricular ejection fraction (LVEF) (≥55 percent as
measured on echocardiography or multiple gated
acquisition [MUGA] scanning) were eligible. Car-
diac exclusion criteria included a history of docu-
mented congestive heart failure, coronary artery dis-
ease with previous Q-wave myocardial infarction,
angina pectoris requiring medication, uncontrolled
hypertension, clinically significant valvular disease,
and unstable arrhythmias.
 
administration of trastuzumab 
 
Trastuzumab was administered intravenously over a
90-minute period at all doses. Patients were closely
observed for at least six hours after the start of the
first dose of 8 mg per kilogram of body weight of
trastuzumab. The second and all subsequent main-
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Figure 1. Consolidated Standards of Reporting Trials (CONSORT) Chart of the Herceptin Adjuvant (HERA) Trial.
 
A total of 5090 women were enrolled between December 2001 and March 2005, for 5081 of whom information was avail-
able for analysis. IHC denotes immunohistochemistry, FISH fluorescence in situ hybridization, and LVEF left ventricular 
ejection fraction.
Diagnosis
Local determination of
HER2-positive invasive breast cancer
 2 Yr of Trastuzumab
Initial dose 8 mg/kg, maintenance
dose 6 mg/kg every 3 wk for 2 yr
1694 Patients
1 Yr median follow-up (range, 0–36 mo)
128 Disease-free–survival
events
No further data released by
independent data-monitoring
committee
Patients continue treatment
and follow-up as planned
220 Disease-free–survival
events
3 Patients started trastuzumab
(1710 patients in the
safety analyses)
Patients may elect to start
trastuzumab between June
and December 2005
127 Disease-free–survival
events
20 Patients never started
trastuzumab
(1677 patients in the
safety analyses)
Patients continue treatment
and follow-up as planned
Primary Treatment
Surgery and adjuvant or neoadjuvant chemotherapy,
or both, with or without radiation therapy
Confirmation of HER2-positive invasive breast cancer
(IHC 3+ or FISH+ by central review laboratory)
and LVEF ≥55 percent after primary treatment
Randomization
1 Yr of Trastuzumab
Initial dose 8 mg/kg, maintenance
dose 6 mg/kg every 3 wk for 1 yr
1694 Patients
Observation
1693 Patients
 
tenance doses were 6 mg per kilogram given every
three weeks. Actual body weight was used to calcu-
late the dose. If the administration of trastuzumab
was delayed by more than seven days, treatment was
restarted at the level of the initial dose of 8 mg per ki-
logram, which was followed by the usual mainte-
nance dose (6 mg per kilogram every three weeks).
If nonhematologic grade 3 or 4 toxic effects oc-
curred, trastuzumab was temporarily withheld un-
til recovery to grade 2 or lower; it was discontinued
if the recovery took more than five weeks, if the
severe side effect recurred on readministration of
trastuzumab, or if symptomatic congestive heart
failure and an LVEF of 45 percent or less developed
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Table 1. Baseline Characteristics of the Patients, Tumors, and Primary Treatments (Intention-to-Treat Groups).*
Variable
1 Yr of Trastuzumab
(N=1694)
Observation
(N=1693)
 
Region — no. (%)
Western and Northern Europe, Canada, South Africa, Australia, 
New Zealand
1208 (71.3) 1222 (72.2)
Asia Pacific, Japan 203 (12.0) 202 (11.9)
Eastern Europe 189 (11.2) 175 (10.3)
Central and South America 94 (5.5) 94 (5.6)
Race — no. (%)†
White 1411 (83.3) 1406 (83.0)
Asian 210 (12.4) 207 (12.2)
Black 12 (0.7) 8 (0.5)
Other 57 (3.4) 67 (4.0)
Missing 4 (0.2) 5 (0.3)
Age — no. (%)
<35 yr 128 (7.6) 123 (7.3)
35–49 yr 751 (44.3) 739 (43.7)
50–59 yr 538 (31.8) 553 (32.7)
≥60 yr 274 (16.2) 275 (16.2)
Missing 3 (0.2) 3 (0.2)
Median age — yr 49 49 
Menopausal status at randomization (after completion of chemotherapy) 
— no. (%)
Premenopausal 272 (16.1) 261 (15.4)
Uncertain 642 (37.9) 629 (37.2)
Postmenopausal 779 (46.0) 797 (47.1)
Missing 1 (0.1) 6 (0.4)
Nodal status — no. (%)
Not assessed (neoadjuvant chemotherapy) 186 (11.0) 172 (10.2)
Negative 543 (32.1) 557 (32.9)
1–3 Positive nodes 482 (28.5) 490 (28.9)
≥4 Positive nodes 480 (28.3) 473 (27.9)
Missing 3 (0.2) 1 (0.1)
Pathological tumor size — no. (%)
Not assessed (neoadjuvant chemotherapy) 186 (11.0) 172 (10.2)
0–2 cm 664 (39.2) 683 (40.4)
>2–5 cm 756 (44.6) 723 (42.7)
>5 cm 75 (4.4) 97 (5.7)
Missing 13 (0.8) 18 (1.1)
Hormone-receptor status — no. (%)‡§
Estrogen-receptor–negative and progesterone-receptor–negative 798 (47.1) 817 (48.3)
Estrogen-receptor–negative and progesterone-receptor–positive 88 (5.2) 85 (5.0)
Estrogen-receptor–negative and progesterone-receptor unknown 32 (1.9) 27 (1.6)
Estrogen-receptor–positive and progesterone-receptor– positive 526 (31.1) 459 (27.1)
Estrogen-receptor–positive and progesterone-receptor–negative 210 (12.4) 246 (14.5)
Estrogen-receptor–positive and progesterone-receptor unknown 36 (2.1) 59 (3.5)
Estrogen-receptor unknown and progesterone-receptor–positive 1 (0.1) 0
Missing 3 (0.2) 0
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* Because of rounding, not all percentages total 100.
† Race was determined on the basis of case report forms.
‡ P<0.05, but the difference between the two groups does not influence the results.
§ Hormone-receptor status was assessed at the local participating institution.
 
¶Some patients received more than one type of adjuvant endocrine therapy.
 
Table 1. (Continued.)
Variable
1 Yr of Trastuzumab
(N=1694)
Observation 
(N=1693)
 
Histologic grade of tumor — no. (%)
3 (Poorly differentiated) 1015 (59.9) 1012 (59.8)
2 (Moderately differentiated) 546 (32.2) 554 (32.7)
1 (Well differentiated) 45 (2.7) 42 (2.5)
Not assessed 75 (4.4) 76 (4.5)
Missing 13 (0.8) 9 (0.5)
Surgery for the primary tumor — no. (%)
Breast-conserving procedure 720 (42.5) 704 (41.6)
Mastectomy 972 (57.4) 987 (58.3)
Missing 2 (0.1) 2 (0.1)
Previous radiotherapy — no. (%)
Yes 1308 (77.2) 1275 (75.3)
No 383 (22.6) 416 (24.6)
Missing 3 (0.1) 2 (0.1)
Type of adjuvant or neoadjuvant chemotherapy, or both — no. (%)
No anthracyclines 102 (6.0) 104 (6.1)
Anthracyclines, no taxanes 1151 (67.9) 1156 (68.3)
Doxorubicin-based regimen at any time 397 (23.4) 416 (24.6)
Epirubicin-based regimen only 754 (44.5) 740 (43.7)
Anthracyclines and taxanes 440 (26.0) 433 (25.6)
Concurrent 103 (6.1) 105 (6.2)
Sequential 337 (19.9) 328 (19.4)
Paclitaxel 256 (15.1) 249 (14.7)
Docetaxel 184 (10.9) 184 (10.9)
Missing 1 (0.2) 0 
Median cumulative dose of anthracyclines — mg/m
 
2
 
Doxorubicin-based regimen at any time 239  238
Epirubicin-based regimen only 397 405
Adjuvant endocrine therapy (861 patients in trastuzumab group and 849 in 
observation group with estrogen-receptor–positive or proges-
terone-receptor–positive status) — no. (%)‡
No 87 (10.1) 60 (7.1)
Yes¶ 774 (89.9) 789 (92.9)
Tamoxifen 683 (79.3) 693 (81.6)
Aromatase inhibitor 143 (16.6) 165 (19.4)
Ovarian-function suppressive therapy or ablation 148 (17.2) 143 (16.8)
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or an LVEF of less than 50 percent with an absolute
reduction of at least 10 percent from baseline de-
veloped. In patients without symptoms of conges-
tive heart failure, the same criteria for left ventric-
ular function were used to withhold treatment.
Trastuzumab was discontinued if, in asymptom-
atic patients, left ventricular function did not re-
turn to a level above the criteria for withholding
treatment after the therapy was stopped for three
weeks.
 
follow-up procedures
 
All patients adhered to the same schedule of fol-
low-up visits, which required the recording of symp-
toms, side effects (graded according to the Na-
tional Cancer Institute Common Toxicity Criteria
[NCI-CTC] version 2.0), and findings on clinical
examination every three months for the first two
years, with hematologic and chemistry studies per-
formed every six months. These assessments are
scheduled to occur annually for year 3 to year 10.
Annual chest radiography is required to year 5 and
annual mammography to year 10.
 
cardiac monitoring
 
Cardiac monitoring in the trastuzumab group and
the observation group included responses to a car-
diac questionnaire, physical examination, 12-lead
 
* CHF denotes congestive heart failure, and LVEF left ventricular ejection fraction.
† Infection (22 patients [1.3 percent] in the trastuzumab group vs. 7 patients [0.4 percent] in the observation group) and 
vascular disorder (20 patients [1.2 percent] vs. 9 patients [0.5 percent], respectively) were the only grade 3 or 4 adverse 
events with an incidence greater than 1 percent in either group.
‡ Infection (29 patients [1.7 percent] in the trastuzumab group vs. 10 patients [0.6 percent] in the observation group) and 
cardiac disorder (17 patients [1.0 percent] vs. 4 patients [0.2 percent], respectively) were the only serious adverse events 
with an incidence greater than 1 percent in either group.
§ The fatal events in the trastuzumab group were of cerebral hemorrhage (1 patient), cerebrovascular accident (1 pa-
tient), sudden death (1 patient), appendicitis (1 patient), and death from unknown causes (2 patients).
¶ The fatal events in the observation group were cardiac failure (1 patient), suicide (1 patient), and death from unknown 
causes (1 patient).
¿ Reasons for withdrawal were reported as adverse event (5.5 percent of patients), refusal to continue (2.5 percent of pa-
tients), or other (0.5 percent of patients).
**Death from cardiac causes was defined as death due to CHF, myocardial infarction, documented primary arrhythmia, or 
sudden unexpected death within 24 hours after a definite or probable cardiac event without a documented alternative 
cause.
††Severe CHF was defined as New York Heart Association functional class III or IV, as confirmed by a cardiologist, and a 
decrease in the ejection fraction of 10 percentage points or more from baseline to an LVEF of less than 50 percent at any 
time. This category does not include death from cardiac causes.
‡‡Symptomatic CHF, which includes severe CHF, was defined as CHF that was considered symptomatic by a cardiologist, 
and a decrease in the ejection fraction of 10 percentage points or more from baseline to an LVEF of less than 50 percent 
at any time. This category does not include death from cardiac causes but does include severe CHF. The age distribu-
tion among patients in the trastuzumab group who had symptomatic CHF, including severe CHF (median age, 51 
years; range, 30 to 69), was not significantly different from that in the study population (P=0.21).
§§ Decrease in LVEF was defined as a decrease in the ejection fraction of 10 percentage points or more from baseline to an 
LVEF of less than 50 percent at any time. Percentages are based on 1595 patients in the trastuzumab group and 1540 
 
patients in the observation group who had a post-screening LVEF assessment.
 
Table 2. Adverse Events, with a Special Focus on Cardiotoxicity, among Patients Included in the Safety Analysis.*
Adverse Event 
1 Yr of 
Trastuzumab
(N=1677)
Observation
(N=1710) P Value
 
no. (%)
 
Patients with at least one grade 3 or 4 event† 132 (7.9) 75 (4.4) <0.001
Patients with at least one serious adverse event‡ 117 (7.0) 81 (4.7) 0.007
Fatal adverse events 6 (0.4)§ 3 (0.2)¶ 0.34
Treatment withdrawals¿ 143 (8.5) —
Cardiac events
Death from cardiac causes** 0 1 (0.06) 1.00
Severe CHF†† 9 (0.54) 0 0.002
Symptomatic CHF, including severe CHF‡‡ 29 (1.73) 1 (0.06) <0.001
Decrease in LVEF§§ 113 (7.08) 34 (2.21) <0.001
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electrocardiogram, and an assessment of LVEF by
echocardiography
 
15
 
 or MUGA scanning at base-
line and 3, 6, 12, 18, 24, 30, 36, and 60 months af-
ter randomization. Cardiac events are described in
Table 2. A core laboratory reviewed the echocardio-
grams, and data management and clinical science
staff reviewed the MUGA scan results of the first
900 patients who were followed for six months.
Three prespecified interim cardiac safety analyses
were performed after 300, 600, and 900 patients had
been enrolled and treated for at least six months.
An absolute difference of more than 4 percentage
points in the incidence of severe congestive heart
failure or cardiac death between the trastuzumab
group and the observation group would have trig-
gered a recommendation by the independent data-
monitoring committee to stop or modify the trial.
 
statistical analysis
 
Enrollment of 4482 patients was planned to detect
a 23 percent relative reduction in the risk of a dis-
ease-free–survival event with 80 percent power, with
the use of a two-sided significance level of 2.5 per-
cent for each comparison: two years of trastuzumab
versus observation and one year of trastuzumab ver-
sus observation. A total of 951 disease-free–survival
events were required for the final analysis. One in-
terim efficacy analysis was planned after 475 events,
with a specified significance level of P≤0.001 re-
quired, with the use of a sequential plan according
to the O’Brien–Fleming boundary as implement-
ed by Lan and DeMets.
 
16
 
 The independent data-
monitoring committee reviewed data on patient
enrollment, deaths, compliance, and safety every
six months and conducted the interim cardiac safe-
ty and efficacy reviews as preplanned.
The efficacy analyses were conducted according
to the intention-to-treat principle. Chi-square tests
for categorical data and log-rank tests for time-to-
event end points provided two-sided P values. Kap-
lan–Meier curves are presented. Cox proportional-
hazards regression analysis was used to estimate
hazard ratios and 95 percent confidence intervals.
 
interim efficacy analysis
 
The 475 disease-free-survival events needed for
the interim efficacy analysis were recorded in the
database on March 29, 2005, and the database was
locked on April 8, 2005; results were reviewed by
the independent data-monitoring committee on
April 25, 2005. The independent data-monitoring
committee recommended release of the results be-
cause improvements in disease-free survival were
highly significant, crossing the sequential bound-
ary for both one year and two years of trastuzumab,
as compared with observation. After a median fol-
low-up period of 1 year (range, 0 to 36 months),
the independent data-monitoring committee re-
leased detailed information only for the groups as-
signed to 1 year of treatment with trastuzumab or
observation. These groups are the focus of this re-
port; evaluation of the group assigned to two years
of treatment with trastuzumab is ongoing.
 
study population
 
Between December 2001 and March 2005, 5081
women for whom information was available for
analysis were enrolled in the study. Of these, 1694
results
 
* Almost 60 percent of the recurrences occurred in patients with estrogen-recep-
tor–negative and progesterone-receptor–negative tumors (48 percent of the 
 
study cohort).
 
Table 3. Efficacy End-Point Events (Intention-to-Treat Groups).
Event
1 Yr of 
Trastuzumab
(N=1694)
Observation
(N=1693)
 
no. (%)
 
Disease-free–survival events
 
Any recurrence, second primary event, or death 
without prior recurrence*
127 (7.5) 220 (13.0)
Local recurrence 17 (1.0) 37 (2.2)
Regional recurrence 10 (0.6) 13 (0.8)
Distant recurrence (site) 85 (5.0) 154 (9.1)
Soft tissue 6 (0.3) 19 (1.1)
Skeletal 24 (1.4) 38 (2.2)
Central nervous system 21 (1.2) 15 (0.9)
Other visceral site 34 (2.0) 82 (4.8)
Contralateral breast cancer 6 (0.4) 7 (0.4)
Second nonbreast malignant disease 3 (0.2) 6 (0.4)
Death without prior recurrence 6 (0.4) 3 (0.2)
 
Death
 
From any cause 29 (1.7) 37 (2.2)
Breast-cancer related 23 (1.4) 34 (2.0)
Without cancer event 6 (0.4) 3 (0.2)
Cardiac failure 0 1 (0.1)
Cerebral hemorrhage 1 (0.1) 0
Cerebrovascular accident 1 (0.1) 0
Other cause 2 (0.1) 1 (0.1)
Unknown cause 2 (0.1) 1 (0.1)
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women were assigned to the trastuzumab group
receiving the drug for one year and 1693 women
were assigned to the observation group (Fig. 1).
HER2-positive status as assessed by the central lab-
oratory was IHC 3+ without FISH testing among
67 percent of the patients. Table 1 lists baseline
characteristics of the patients, tumors, and primary
treatment. The baseline characteristics of the two
groups were well balanced (Table 1). The median
age was 49 years, one third of the patients had node-
negative disease, and 48 percent of the patients had
hormone-receptor–negative tumors.
Chemotherapy was anthracycline-based in 94
percent of patients; 26 percent received a taxane,
76 percent received radiotherapy, and tamoxifen
was the predominant endocrine therapy. The me-
dian time between diagnosis of breast cancer and
the initiation of trastuzumab was 8.4 months (inter-
quartile range, 7.1 to 9.6 months).
There were major eligibility violations in 11 pa-
tients (8 patients in the trastuzumab group and 3
patients in the observation group): LVEF less than
55 (4 patients), status of HER2-positive not cen-
trally confirmed (3 patients), microinvasive breast
cancer (3 patients), and metastatic disease (1 pa-
tient). In addition, 39 patients in the trastuzumab
group and 52 patients in the observation group had
node-negative disease with tumors 1 cm in diame-
ter or less.
 
adverse effects and cardiac safety
 
Twenty patients assigned to one year of trastuzu-
mab did not receive treatment, and three patients as-
signed to observation received trastuzumab. These
23 patients are included in the alternative group for
the safety analyses (Fig. 1 and Table 2). Table 2
shows a higher incidence of NCI-CTC grade 3 or
4 adverse events and serious adverse events in the
trastuzumab group than in the observation group.
There were six fatal adverse events in the trastuz-
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Figure 2. Kaplan–Meier Curves Showing Disease-free 
Survival (Panel A), Time to Distant Recurrence (Panel B), 
and Overall Survival (Panel C).
 
The hazard ratios (with 95 percent confidence intervals 
and P values) are for the patients assigned to receive 
trastuzumab for one year, as compared with those as-
signed to observation, and were obtained from the unad-
justed Cox model. DFS denotes disease-free survival, 
CI confidence interval, TTDR time to distant recurrence, 
and OS overall survival.
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umab group and three in the observation group
(Table 2).
There was one cardiac death in the observa-
tion group, and nine patients (0.54 percent) in the
trastuzumab group had severe congestive heart fail-
ure (as defined in Table 2). Symptomatic conges-
tive heart failure, including the nine severe cases (as
defined in Table 2), occurred in 1.7 percent of pa-
tients in the trastuzumab group and 0.06 percent
of patients in the observation group; a decrease in
LVEF (as defined in Table 2) was noted on at least
one assessment among 7.1 percent of patients in
the trastuzumab group and among 2.2 percent of
those in the observation group. 
 
treatment compliance
 
Trastuzumab was stopped before completion of
the planned one-year treatment among 143 patients
(8.5 percent) for reasons other than relapse. Rea-
sons included an adverse event among 5.5 percent
of patients, the patient’s refusal among 2.5 per-
cent, and other reasons among 0.5 percent.
 
efficacy
 
A total of 127 disease-free–survival events were re-
ported in the trastuzumab group and 220 in the ob-
servation group (Table 3). The unadjusted hazard
ratio for the risk of an event in the trastuzumab
group, as compared with the observation group,
was 0.54 (95 percent confidence interval, 0.43 to
0.67; P<0.0001 by the log-rank test, crossing the
interim-analysis boundary) (Fig. 2A), which corre-
sponded to an absolute benefit in disease-free sur-
vival of 8.4 percentage points at two years (95 per-
cent confidence interval, 2.1 to 14.8).
Approximately two thirds of the reported first
events were distant metastases (Table 3). The haz-
ard ratio for time to a distant recurrence in the tras-
tuzumab group, as compared with the observation
group, was 0.49 (95 percent confidence interval,
0.38 to 0.63; P<0.0001) (Fig. 2B). With 29 deaths
in the trastuzumab group and 37 in the observation
group, the estimated reduction in the hazard ratio
for death (24 percent) was not statistically signifi-
cant (Fig. 2C). There was no evidence of substantial
heterogeneity in the relative treatment effect among
the subgroups (Fig. 3).
This study shows that trastuzumab can benefit
women with HER2-positive breast cancer when giv-
en after completion of adjuvant chemotherapy. As
compared with observation after primary therapy
(including surgery with or without radiotherapy and
neoadjuvant or adjuvant chemotherapy), trastuzu-
mab given after primary therapy reduced the rate of
recurrence, particularly distant recurrence, by ap-
proximately 50 percent. This degree of benefit in
early breast cancer is the largest to be reported since
the introduction of tamoxifen in hormone-recep-
tor–positive disease. This trial is the culmination
of a collaboration between basic research scien-
tists and clinical investigators over the past two
decades.
 
1-4,17-33
 
The interpretation of our results must take into
account the very short follow-up period — a medi-
an of 12 months and a maximum of 36 months.
However, the pattern of early, and largely distant,
relapse found among patients with HER2-positive
breast cancer, and the clinically and statistically
significant reduction in the risk of relapse achieved
with trastuzumab, justified release of the results of
the interim efficacy analysis.
We acknowledge that we have only an incom-
plete picture of the risks associated with trastuzu-
mab. The risk of cardiotoxicity is currently low in
our trial, but this could change with longer follow-
up. Another concern is that longer follow-up may
show that trastuzumab is not effective in reducing
the incidence of disease recurrence in the central
nervous system. Brain metastases developed in ap-
proximately one third of the women receiving tras-
tuzumab as treatment for advanced breast cancer,
despite control of systemic disease.
 
34
 
 It is not clear
whether such central nervous system metastases re-
flect aggressive disease or poor penetration of tras-
tuzumab into the brain.
Will the benefit of adjuvant trastuzumab accrue
to all women who have HER2-positive breast cancer
discussion
 
Figure 3 (facing page). Analyses of Disease-free Survival 
According to Subgroup.
 
The hazard ratios (with 95 percent confidence intervals) 
are for the patients assigned to trastuzumab for one year, 
as compared with those assigned to observation, and 
were obtained from the unadjusted Cox model. The solid 
vertical line indicates a hazard ratio of 0.54, which is the 
value for all patients, and the dashed vertical line indi-
cates a hazard ratio of 1.00, which is the null-hypothesis 
value. The size of the squares is proportional to the num-
ber of events in the subgroup. CI denotes confidence in-
terval, N.Z. New Zealand, ER estrogen receptor, and PgR 
progesterone receptor.
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who are treated outside clinical trials? Women with
small (≤1 cm in diameter), node-negative invasive
tumors were not eligible for this trial. Although at a
median of one year of follow-up, trastuzumab im-
proved the disease-free survival in all subgroups
(Fig. 3), further follow-up may show that the mag-
nitudes of absolute benefit differ across subgroups.
For example, almost 60 percent of the disease-free–
survival events observed so far occurred in the hor-
mone-receptor–negative cohort (48 percent of the
patients), but we cannot rule out the possibility that
in the future disease-free–survival events may oc-
cur disproportionately more often among patients
in the subgroup with hormone-receptor–positive
tumors. By design, women with cardiac risk factors
and an LVEF of less than 55 percent after completion
of chemotherapy with or without radiotherapy were
excluded from the study, and our data are not ap-
plicable to the treatment of such women.
In our study, HER2 overexpression or 
 
HER2
 
 am-
plification had to be confirmed by a central labora-
tory before randomization, thereby reducing the
risk of false positive results. It is our view that adju-
vant trastuzumab should be considered only if the
HER2-positive status of the tumor has been deter-
mined by a high-volume laboratory with quality-
control procedures.
 
35
 
The results of the HERA trial should be widely
applicable to women with HER2-positive breast
cancer for the following reasons: different types of
neoadjuvant or adjuvant chemotherapy were al-
lowed before the initiation of trastuzumab; the
schedule of administration of one dose every three
weeks, which was shown in the metastatic setting
to have efficacy, side effects, and pharmacokinetics
similar to those of the weekly schedule,
 
6
 
 was used;
and patients with node-negative disease were in-
cluded. It appears that trastuzumab is effective re-
gardless of the type of chemotherapeutic regimens
received before treatment with trastuzumab and the
extent of nodal involvement.
We do not know if introducing trastuzumab early
in the course of adjuvant systemic therapy, concom-
itantly with chemotherapy, could further improve
the outcome. The question of timing is likely to re-
main unanswered, because early administration of
trastuzumab, as studied in ongoing trials,
 
36,37 
 
re-
quires the drug to be used concurrently with specific
chemotherapy regimens that are hypothesized to
enhance the effectiveness of trastuzumab.
 
30,32
 
The results of this trial indicate that one year of
adjuvant trastuzumab should be considered a stan-
dard option on completion of locoregional thera-
py and neoadjuvant or adjuvant chemotherapy for
women who fulfill the study eligibility criteria used
in the HERA trial.
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